Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...